{"id":"candesartan-cilexetil-chlorthalidone-amlodipine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia (candesartan component)"},{"rate":null,"effect":"Hypokalemia (chlorthalidone component)"},{"rate":null,"effect":"Peripheral edema (amlodipine component)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:26:23.218382","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan cilexetil blocks angiotensin II type 1 receptors to reduce vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion. Amlodipine is a dihydropyridine calcium channel blocker that causes vasodilation. Together, these three agents target complementary pathways to achieve additive blood pressure reduction.","oneSentence":"This triple-combination antihypertensive reduces blood pressure through angiotensin II receptor blockade, thiazide diuresis, and calcium channel inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:50.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (blood pressure control in patients requiring triple-agent therapy)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2025 Oct","pmid":"40892621","title":"Efficacy and Safety of a Novel Triple Single-Pill for Uncontrolled Hypertension: The OPTION TREAT Trial.","journal":"JACC. Advances"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"candesartan cilexetil + chlorthalidone + amlodipine","genericName":"candesartan cilexetil + chlorthalidone + amlodipine","companyName":"Hospital Israelita Albert Einstein","companyId":"hospital-israelita-albert-einstein","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination antihypertensive reduces blood pressure through angiotensin II receptor blockade, thiazide diuresis, and calcium channel inhibition. Used for Hypertension (blood pressure control in patients requiring triple-agent therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}